-+ 0.00%
-+ 0.00%
-+ 0.00%

Artiva Biotherapeutics names Diego Miralles president, head of R&D

PUBT·05/19/2026 12:08:39
Listen to the news
Artiva Biotherapeutics names Diego Miralles president, head of R&D
  • Artiva Biotherapeutics named Diego Miralles as president and head of research and development, adding a senior drug developer as the company advances its AlloNK cell therapy in autoimmune diseases.
  • Miralles previously served as CEO of Laronde and earlier built Vividion Therapeutics as CEO; he also held senior roles at Adaptive Biotechnologies and Johnson & Johnson, including work on antivirals such as PREZISTA and INTELENCE.
  • He has been on Artiva’s board since May 2024; the appointment comes as the company prepares for registrational development in refractory rheumatoid arthritis and targets a first BLA filing for AlloNK in 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190800PRIMZONEFULLFEED9722570) on May 19, 2026, and is solely responsible for the information contained therein.